Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00839306 · ClinicalTrials.gov registry record · Phase 3

Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)

A Phase 3 study of Gastroesophageal Reflux Disease (GERD), sponsored by Eisai.

Completed
Registry status
Phase 3
Development phase
240
Enrollment target
4
Study locations

NCT00839306 is a Phase 3 study of Gastroesophageal Reflux Disease (GERD) that has completed, run by Eisai. The registered enrollment target is 240 participants, below the 2,485-participant average among 5 other Gastroesophageal Reflux Disease (GERD) trials with a reported enrollment target (90% lower). The trial reports 4 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00839306, a Phase 3 study of Gastroesophageal Reflux Disease (GERD), has completed, sponsored by Eisai.

COMPLETED
Registry status
Phase 3
Development phase
240 participants
Enrollment target
4
Study locations

Study Summary

The purpose of this study is to compare the efficacy of rabeprazole extended release 50 mg (once daily) versus ranitidine 150 mg (twice daily) in the maintenance of complete healing in subjects with healed erosive gastroesophageal reflux disease (eGERD).

Conditions Studied

Gastroesophageal Reflux Disease (GERD)

Interventions

  • DRUG Rabeprazole ER
  • DRUG Ranitidine

Study Locations (4)

Illinois

  • Associates, Ltd. - Moline
  • Midwest Clinical - Moline
  • Research - Moline
  • - Moline

Trial Details

FieldValue
Enrollment Target 240 participants
Start Date 2008-08
Est. Completion 2010-01
Phase Phase 3

Sponsor

Eisai

287 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00839306

The ClinicalTrials.gov registry entry for NCT00839306 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,485-participant average among 5 other Gastroesophageal Reflux Disease (GERD) trials with a reported enrollment target (90% lower). The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Gastroesophageal Reflux Disease (GERD) appearing as the primary indexed condition, and to 2 interventions - of which Rabeprazole ER is the first listed.

NCT00839306 reports 4 study locations spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT00839306 about?

NCT00839306 is a clinical study titled "Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)". The purpose of this study is to compare the efficacy of rabeprazole extended release 50 mg (once daily) versus ranitidine 150 mg (twice daily) in the maintenance of complete healing in subjects with healed erosive gastroesophageal reflux disease (eGERD).

What is the current status of trial NCT00839306?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 240 participants. The study started on 2008-08. Estimated completion is 2010-01.

What conditions does trial NCT00839306 study?

This clinical trial studies the following conditions: Gastroesophageal Reflux Disease (GERD).

What interventions are being tested in trial NCT00839306?

The interventions under investigation include: Rabeprazole ER (DRUG), Ranitidine (DRUG).

Who is sponsoring clinical trial NCT00839306?

This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00839306 being conducted?

This trial has 4 study locations across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gastroesophageal Reflux Disease (GERD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Gastroesophageal Reflux Disease (GERD)

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.